Vaccine production is a complex and highly regulated process involving multiple stages, from research and development to manufacturing and distribution. The primary goal is to produce safe, effective, and consistently high-quality vaccines to address various infectious diseases. The production process begins with the selection of the vaccine's target pathogen or antigen. Depending on the vaccine type, antigens may be derived from inactivated or attenuated pathogens, subunit proteins, or genetic material like DNA or mRNA. Large-scale manufacturing involves cultivating the chosen antigen in cell cultures, eggs, or bioreactors, followed by purification and formulation. Adjuvants and stabilizers are carefully added to enhance the vaccine's immunogenicity and stability. Quality control measures ensure the consistency, purity, and safety of each batch. Rigorous testing, including clinical trials, assesses the vaccine's safety and efficacy in diverse populations. Global distribution requires adherence to cold chain logistics to maintain vaccine potency. Collaboration between manufacturers, regulatory agencies, and international organizations is crucial for efficient vaccine production and distribution, ensuring widespread accessibility and contributing to global health initiatives. Advances in vaccine production technologies, such as cell-based and recombinant methods, continue to improve efficiency, scalability, and the overall impact of vaccination programs worldwide.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States